Categorynews

Teva to Host Conference Call to Discuss First Quarter 2019 Financial Results at 8 a.m. ET on May 2, 2019

April 8, 2019 Off By BusinessWire

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced that it will issue a press release on its first quarter 2019
financial results on Thursday, May 2, 2019 at 7:00 a.m. ET. Following
the release, Teva will conduct a conference call and live webcast on the
same day, at 8:00 a.m. ET.

In order to participate, please dial the following numbers (at least 10
minutes before the scheduled start time): United States 1-866-966-1396;
Israel 1-809-203-624 or International +44 (0) 2071 928000; passcode: 9470199.
For a list of other international toll-free numbers, click here.

A live webcast of the call will also be available on Teva’s website at: http://ir.tevapharm.com.
Please log in at least 10 minutes prior to the conference call in order
to download the applicable audio software.

Following the conclusion of the call, a replay of the webcast will be
available within 24 hours on the Company’s website by calling United
States 1-866-331-1332; International +44 (0) 3333009785; passcode: 9470199.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been
developing and producing medicines to improve people’s lives for more
than a century. We are a global leader in generic and specialty
medicines with a portfolio consisting of over 35,000 products in nearly
every therapeutic area. Around 200 million people around the world take
a Teva medicine every day, and are served by one of the largest and most
complex supply chains in the pharmaceutical industry. Along with our
established presence in generics, we have significant innovative
research and operations supporting our growing portfolio of specialty
and biopharmaceutical products. Learn more at www.tevapharm.com.

Teva Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, which
are based on management’s current beliefs and expectations and are
subject to substantial risks and uncertainties, both known and unknown,
that could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to:

our ability to successfully compete in the marketplace, including:
that we are substantially dependent on our generic products;
competition for our specialty products, especially COPAXONE^®,
our leading medicine, which faces competition from existing and
potential additional generic versions and orally-administered
alternatives; the uncertainty of commercial success of AJOVY^® or
AUSTEDO^®; competition from companies with greater resources
and capabilities; efforts of pharmaceutical companies to limit the use
of generics, including through legislation and regulations;
consolidation of our customer base and commercial alliances among our
customers; the increase in the number of competitors targeting generic
opportunities and seeking U.S. market exclusivity for generic versions
of significant products; price erosion relating to our products, both
from competing products and increased regulation; delays in launches
of new products and our ability to achieve expected results from
investments in our product pipeline; our ability to take advantage of
high-value opportunities; the difficulty and expense of obtaining
licenses to proprietary technologies; and the effectiveness of our
patents and other measures to protect our intellectual property rights;
our substantial indebtedness, which may limit our ability to incur
additional indebtedness, engage in additional transactions or make new
investments, may result in a further downgrade of our credit ratings;
and our inability to raise debt or borrow funds in amounts or on terms
that are favorable to us;
our business and operations in general, including: failure to
effectively execute our restructuring plan announced in December 2017;
uncertainties related to, and failure to achieve, the potential
benefits and success of our senior management team and organizational
structure; harm to our pipeline of future products due to the ongoing
review of our R&D programs; our ability to develop and commercialize
additional pharmaceutical products; potential additional adverse
consequences following our resolution with the U.S. government of our
FCPA investigation; compliance with sanctions and other trade control
laws; manufacturing or quality control problems, which may damage our
reputation for quality production and require costly remediation;
interruptions in our supply chain; disruptions of our or third party
information technology systems or breaches of our data security; the
failure to recruit or retain key personnel; variations in intellectual
property laws that may adversely affect our ability to manufacture our
products; challenges associated with conducting business globally,
including adverse effects of political or economic instability, major
hostilities or terrorism; significant sales to a limited number of
customers in our U.S. market; our ability to successfully bid for
suitable acquisition targets or licensing opportunities, or to
consummate and integrate acquisitions; and our prospects and
opportunities for growth if we sell assets;
compliance, regulatory and litigation matters, including: costs and
delays resulting from the extensive governmental regulation to which
we are subject; the effects of reforms in healthcare regulation and
reductions in pharmaceutical pricing, reimbursement and coverage;
increased legal and regulatory action in connection with public
concern over the abuse of opioid medications in the U.S.; governmental
investigations into selling and marketing practices; potential
liability for patent infringement; product liability claims; increased
government scrutiny of our patent settlement agreements; failure to
comply with complex Medicare and Medicaid reporting and payment
obligations; and environmental risks;
other financial and economic risks, including: our exposure to
currency fluctuations and restrictions as well as credit risks;
potential impairments of our intangible assets; potential significant
increases in tax liabilities; and the effect on our overall effective
tax rate of the termination or expiration of governmental programs or
tax benefits, or of a change in our business;

and other factors discussed in our Annual Report on Form 10-K for the
year ended December 31, 2018, including the sections captioned “Risk
Factors.” Forward-looking statements speak only as of the date on which
they are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise. You
are cautioned not to put undue reliance on these forward-looking
statements.